Header Logo

Connection

Carlos Iribarren to Antibodies, Anti-Idiotypic

This is a "connection" page, showing publications Carlos Iribarren has written about Antibodies, Anti-Idiotypic.
Connection Strength

0.119
  1. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014 Sep; 134(3):560-567.e4.
    View in: PubMed
    Score: 0.119

© 2025 Kaiser Permanente